Evidence map›Paper›PMID 38423785›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024

Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and

Meijuan Jiang, Shiyu Tang, Madeline D Jenkins, Adrian C Lee, Bruny Kenou, Carson Knoer, Jose Montero Santamaria, Shawn Wu, Jeih-San Liow, Sami S Zoghbi and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Meijuan JiangMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Shiyu TangMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Madeline D JenkinsMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Adrian C LeeMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Bruny KenouMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Carson KnoerMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Jose Montero SantamariaMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Shawn WuMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Jeih-San LiowMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Sami S ZoghbiMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Paolo Zanotti-FregonaraMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Robert B InnisMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Sanjay TeluMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland pikev@mail.nih.gov sanjay.telu@nih.gov.
Victor W PikeMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland pikev@mail.nih.gov sanjay.telu@nih.gov.
National Institutes of Health · US

Funding

PET Radiopharmaceutical SciencesZIAMH002793 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PIKE, VICTOR W · 2009 to 2025
$69.8M
Translational Evaluation Of PET RadiotracersZIAMH002795 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI INNIS, ROBERT · 2009 to 2025
$32.0M
Intramural NIH HHS ZIA MH002793
6 · The paper itself

Abstract

Phosphodiesterase-4D (PDE4D) has emerged as a significant target for treating neuropsychiatric disorders, but no PET radioligand currently exists for robustly quantifying human brain PDE4D to assist biomedical research and drug discovery. A prior candidate PDE4D PET radioligand, namely [

Indexed as

BrainCarbon RadioisotopesCyclic Nucleotide Phosphodiesterases, Type 4Macaca mulattaPositron-Emission TomographyAnimalsHumansIsotope LabelingLigandsMalePhosphodiesterase 4 InhibitorsRadiopharmaceuticalsCarbon-11Carbon RadioisotopesCyclic Nucleotide Phosphodiesterases, Type 4LigandsPhosphodiesterase 4 InhibitorsRadiopharmaceuticals11CinhibitorsPETphosphodiesterase-4D (PDE4D)

Identifiers

PMID38423785
PMCPMC11064827
OpenAlexW4392282362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.